According to The Wall Street Journal, citing unnamed knowledgeable sources, the pharmaceutical corporation Pfizer is in talks to buy the biotech company Seagen. It is reported that the negotiations are at an early stage, so “there is no guarantee that the deal will take place.” Last year, negotiations to buy Seagen were conducted by another American pharmaceutical company, Merck, but they did not lead to anything.
If the deal with Pfizer goes through, it will be worth at least $30 billion – Seagen’s current market capitalization is regarding $33 billion. do not affect healthy cells. Seagen’s best-known drug, Adcetris, is used to treat various types of lymphoma.
The acquisition of Seagen will help Pfizer cut sales losses for its patents expiring in the next few years. According to Pfizer forecasts, by 2030 its sales may be reduced by $17 billion. Seagen’s annual sales are now regarding $2 billion. The deal is also supported by the fact that Pfizer has accumulated regarding $23 billion of free cash – largely due to sales of anti-covid vaccines and other drugs. Last year, Pfizer already spent $5 billion to buy Global Blood Therapeutics and $10 billion to buy parts of Biohaven Pharmaceutical’s assets.
